Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT06385418

Fluorouracil Treatment Via Colon for Colorectal Cancer

Led by The Second Hospital of Nanjing Medical University · Updated on 2024-06-26

40

Participants Needed

1

Research Sites

258 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Fluorouracil (5-FU) is a commonly used drug for colorectal cancer (CRC). Thermosensitive hydrogel presents a promising carrier for 5-FU to address challenges encountered with traditional administration methods. We propose an integrated approach utilizing colonic transendoscopic enteral tubing to cover the entire colon flexibly, coupled with a thermo-sensitive gel to enhance the adhesion of 5-FU. This clinical trial aims to assess the feasibility, safety, and efficacy of this approach for treating CRC.

CONDITIONS

Official Title

Fluorouracil Treatment Via Colon for Colorectal Cancer

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Chinese individuals aged 18 to 75 years, male or female
  • Histologically confirmed colorectal cancer with measurable primary lesion according to RECIST 1.1
  • ECOG performance status of 2 or less
  • Expected survival longer than 3 months
  • Multidisciplinary team agreement that adding local chemotherapy is appropriate
  • Adequate organ function including specific blood counts, liver and kidney function, and heart function (LVEF 50%)
  • Women of childbearing potential must have a negative pregnancy test within 7 days before enrollment
  • Sexually active participants agree to use effective contraception during the trial and for 8 weeks after last dose
  • Suitable physical condition and willingness to undergo colonic transendoscopic enteral tubing
  • Willingness to cooperate with physicians and attend regular follow-up visits
  • Agreement to specimen collection and signing informed consent form
Not Eligible

You will not qualify if you...

  • Uncontrolled cardiovascular diseases with risk of serious events during treatment
  • Active severe infections in the gastrointestinal tract
  • Coagulation problems with bleeding tendencies or inadequate anticoagulant control
  • History of immunodeficiency or organ transplantation
  • Other progressive or actively treated cancers requiring intervention, except certain skin or cervical cancers
  • Other serious diseases making participation unsafe
  • Breastfeeding women
  • Known allergy or intolerance to fluorouracil or its components
  • Participation in another drug trial within the past four weeks
  • Lack of full legal capacity or restricted legal capacity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China, 210011

Actively Recruiting

Loading map...

Research Team

F

Faming Zhang, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here